Targeting of peg antibody conjugates to islet cells

Details Targeting of peg antibody conjugates to islet cells Targeting of peg antibody conjugates to islet cells

1996-09-20

1998-12-29

Feisee, Lila

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

4241791, 514772, 5147721, A61K 39395, A61K 3944, A61K 4700

Patent

active

058537236

ABSTRACT:
A method for delaying onset of insulin dependent diabetes mellitus (IDDM) in an individual predisposed to developing the disease is disclosed. The method comprises administering a composition comprising an immunologically effective monoclonal antibody or fragment thereof against glutamic acid decarboxylase (GAD) coupled to a nonimmunogenic hydrophilic polymer that provides a hydration shell around the monoclonal antibody for inhibiting immune recognition thereof. Poly(ethylene glycol) is a preferred polymer. A method of reducing insulitis in an IDDM patient and a composition therefor are also described.

REFERENCES:
patent: 5200318 (1993-04-01), Rabin et al.
patent: 5349052 (1994-09-01), Delgado et al.
patent: 5512447 (1996-04-01), Baekkeskov et al.
patent: 5512582 (1996-04-01), Capon et al.
Dillnan, Annal Int. Med, 1989, 111:592-603.
Lernmark, J. Int Med, 1996, 240:259-277.
Ham Ann et al, Diabetes Res, 1994, 26: 109-116.
Chang & Grottlieb, J. Neurosci, 1988, 8:2123-2130.
Wu et al, Brain Res, 1986, 373 11-14.
DeAizpurua & Harrison, 1992, 8:133-149.
Ellis & Atkinson, Nasl Med (NY) 1996, 2:148-153.
Harlow & Lane, Antibodies, 1988, Cold Spring Harbor Lab, Cold Spring Harbor, p. 130.
Deschamps, I., Life Table Analysis o the Risk of Type I (Insulin-dependent) Diabetes Mellitus in Siblings According to Islet Cell Antibodies and HLA Markers, 35 Diabetologia 951-57 (1992).
Harrison, L.C., et al, Islet-reactive T Cells Are a Marker of Preclinical Insulin-dependent Diabetes, 89 J. Clin. Invest. 1161-65 (1992).
Wilken, T.J., et al, Autoimmunce Diabetes and the Germ Theory of Disease, 35 Diabetologia 187-89 (1992).
Roll, U., et al, Associations of Anti-GAD Antibodies with Islet Cell Antibodies and Insulin Autoantibodies in First-degree Relatives of type I Diabetes Patients, 43 Diabetes 154-60 (1994).
Zimmet, P.Z., et al, Latent Autoimmunce Diabetes Mellitus in Adults (LADA): the Role of Antibodies to Glutamic Acid Decarboxylase in Diagnosis and Prediction of Insulin Dependency, 11 Diabetic Medicine 299-303 (1994).
Kabanov, 22 J. Contr. Rel. 141-58.
Bradley, B. J., et al, CD 8T Cells Are Not Required for Islet Destruction Induced by a CD4 Islet-Specific T-Cell Clone, 41 Diabetes 1603-08 (1992).
Botazzo, G.F., et al, Islet Cell Antibodies in Diabetes Mellitus with Autoimmune Polyendocrine Deficiency, Lancet 1279-83 (1974).
Dotta, F., et al, Pancreatis Islet Ganglioside Expression in Non-obese Diabetic Mice; Comparison with C57B1/10 Mice and Changes After Autoimmune B-cell Destruction, 130 Endocrinology 37-42 (1992).
Greenbaum, C.J., et al, Improved Specificity of ICA Assays in the Fourth International Immunology of Diabetes Serum Exchange Workshop, 41 Diabetes 1570-74 (1992).
Greenbaum, C.J., et al, Fifth International Serum Exchange Workshop for Insuli Autoantibody (IAA) Standardization, 35 Diabetologia 798-800 (1992).
Landin-Olsson, M., et al, Predictive Value of Islet Cell and Insulin Autoantibodies for Type 1 (Insulin-dependent) Diabetes Mellitus in a Population-based Study of Newly-diagnosed Diabetic and Matched Control Children, 35 Diabetologia 1068-73 (1992).
Levy-Marchal, C., et al, Islet Cell Antibodies in Normal French School Children, 35 Diabetologia 577-82 (1992).
Gottsater, A., et al, Islet Cell Antibodies and Fasting Plasma C-peptie During the First 10 Years After Diagnosis in Patients with Diabetes Mellitus Diagnose in Adult Age, 5 Diab. Nutr. Metab. 243-48 (1992).
Christie, M.R., et al, Binding of Antibodies in Sera from Type 1 Diabetic Patients to Glutamate Decarboxylase from Rat Tissues-Evidence for Antigenic and Non-antigenic Forms of the Enzyme, 35 Diabetologia 380-84 (1992).
Christie, M.R., et al, Antibodies to GAD and Tryptic Fragments of Islet 64K Antigen as Distinct Markers for Development of IDDM--Studies with Identical Twins, 41 Diabetes 782-87 (1992).
DeAizpurua, H.J., et al, Glutamic Acid Decarboxylase in Insulin Dependent Diabetes Mellitus, 8 Diabetes/Metabolism Reviews 133-47 (1992).
Bjork E., et al, GAD Autoantibodies in IDDM, Stiff-Man Syndrome and Autoimmune Polyendocrine Syndrome Type I Recognize Different Eptiopes, 43 Diabetes 161-65 (1994).
Thivolet, C.H., et al, Glutamic Acid Decarboxylase (GAD) Autoantibodies are Additional Predictive Markers of Type I (Insulin-dependent) Diabetes Mellitus in High Risk Individuals, 35 Diabetologia 570-76 (1992).
Serjeantson, S.W., et al, Antibodies to Glutamic Acid Decarboxylase Are Associated with HLA-DR Genotypes in both Australians and Asians with Type I (Insulin-dependent) Diabetes Mellitus, 35 Diabetologia 996-1001 (1992).
Tisch, R., et al Immune Respone to Glutamic Acid Decarboxylase Correlates with Insulitis in Non-obese Diabetic Mice, 366 Nature 72-75 (1993).
Kaufman, D.L., et al, Spontaneous Loss of T-Cell Tolerance to Glutamic Acid Decarboxylase in Murine Insulin-dependent Diabetes, 366 Nature 69-72 (1993).
Lipes, M.A., et al, Progression to Diabetes in Non-obese Diabetic (NOD) Mice with Transgenic T Cell Receptors, 259 Science 1165-69 (1993).
Eisenbarth, G.S., et al, Pathogenesis of Insulin-dependent (Type I) Diabetes Mellitus, in C.R. Kohn & G. Weiz eds., Joslin's Diabetes Mellitus 216-39 (13.sup.th ed., 1994).
Vives, M., et al, Reevaluation of Autoantibodies to Islet Cell Membrane in IDDM--Failure to Detect Islet Cell Surface Antibodies Using Human Islet Cells as Substrate, 41 Diabetes 1624-31 (1992).
Tattersall, R.B., et al, Patient Self-monitoring of Blood Glucose and Refinement of Conventional Insuli Treatment, 70 Am. J. Med. 177-80 (1981).
Fogt, F.J., et al, Development and Evaluation of a Glucose Analyzer for a Glucose-Controlled Insulin Infusion System (Biostator), 24 Clin. Chem. 1366-81 (1978).
Ishihara, K., et al, Glucose Induced Permeation Through a Complex Membrane Consisting of Immobilized glucose Oxidase and a Poly(amine), 16 Polymer J. 625-42 (1984).
Reich, E., et al, Prevention of Diabetes in NOD Mice by Injection of Autoreactive T-lymphocytes, 38 Diabetes 1647-51 (1989).
Lanza, R.P., et al, Xeotransplantation of Canine, Bovine and Porcine Islets in Diabetic Rats without mmunosuppresion, 88 roc. Nat'l Acad. Sci. USA 11100-03 (1991).
Bingley, P.J., et al, Can We Really Predict IDDM? 42 Diabetes 213-20 (1993).
Lernmark, A., Immune Intervention Yes, but for What Reason for Whom, When and How? 35 Diabetologia 1096-98 (1992).
Maki, T., et al, Long-term Abrogation of Autoimmune Diabetes in Non-obese Diabetic Mice by Immunotherapy with Antilymphocyte Serum, 89 Proc. Nat'l Acad. Sci USA 3434-38 (1992).
Petersen, J.S., et al, Neonattal Tolerization With Glutamic Acid Decarboxylase But Not With Bovine Serum Albumin Delays the Onset of Diabetes in NOD Mice, 44 Diabetes 1478-84 (1994).
Pleau, J., et al, Prevention of Autoimmune Diabetes in Nonobese Diabetic Femal Mice by Treatment with Recombinant Glutamic Acid Decarboxylase (GAD 65), 76 Clinical Immunology and Immunopathology, 90-95 (1995).
Panina-Bordignon, P., et al, Cytotoxic T Cells Specific for Glutamic Acid Decarboxylase in Autoimmune Diabetes, 181 J. Exp. Med. 1923-27 (1995).
Weiss, U., et al, In Vitro Stimulation with Glutamic Acid Decarboxylase (GAD65) Leads to an Oligoclonal Response of Perpheral T-Cells in an IDDM Patient, 42 Scand, J. Immunol. 673-78 (1995).
Petersen, J., et al, Glutamic Acid Decarboxylase (GAD65) Autoantibodies in Predicition of .beta.-Cell Function and Remission in Recent-Onset IDDM After Cyclosporin Treatment, 43 Diabetes, 1292-96 (1994).
Verge, C.F., Prediction of Type I Diabetes in First Degree RelativeUsing a Combination of Insulin, GAD, and ICA512bdc/IA-2 Autoantibodies, 45 Diabetes 926-33 (1996).
Sai, P., et al, Immunization of non-obese diabetic (NOD) mice with glutamic acid decarboxylase-derived peptide 524-543 reduces cyclophosphamide-accelerated diabetes, 105 Clin. Exp. Immunol. 330-337 (1996).
Atkinson, M.A., et al, Cellular Immunity to a Determinant Common to Glutamate Decarboxylase and Coxackie Virus in Insulin-dependent Diabetes, 94 J. Clin. Invest. 2125-29 (1994).
Christie, M.R., et al, Antibodies to Islet 37k Antigen, But Not to Glutamate Decarboxylase, Discriminate Rapid Progression to IDDM in Endocrine Aut

Affiliated with

Also associated with

Rating

Targeting of peg antibody conjugates to islet cells does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Targeting of peg antibody conjugates to islet cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Targeting of peg antibody conjugates to islet cells will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1421486